Hans Marcus Bosson
Director Ejecutivo en QUIAPEG PHARMACEUTICALS HOLDING AB .
Cargos activos de Hans Marcus Bosson
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
QUIAPEG PHARMACEUTICALS HOLDING AB | Director/Miembro de la Junta | 01/01/2017 | - |
Director Ejecutivo | 01/01/2017 | - | |
Independent Dir/Board Member | 01/01/2017 | - |
Historial de carrera de Hans Marcus Bosson
Antiguos cargos conocidos de Hans Marcus Bosson.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Fundador | 01/01/1998 | 24/06/2010 |
Presidente | 01/01/1998 | 24/06/2010 | |
Ryda Bruk AB
Ryda Bruk AB Miscellaneous Commercial ServicesCommercial Services Part of Beijerinvest AB, Ryda Bruk AB is a consulting services provider. The company is based in Heby, Sweden. | Director Ejecutivo | - | - |
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Director/Miembro de la Junta | 01/01/2012 | - |
Fundador | 01/01/2012 | - | |
Director Ejecutivo | 01/01/2012 | - | |
BIOARCTIC AB | Director/Miembro de la Junta | - | - |
Formación de Hans Marcus Bosson.
Stockholm School of Economics | Graduate Degree |
University of Stockholm | Graduate Degree |
Estadísticas
Internacional
Suecia | 8 |
Operativa
Director/Board Member | 3 |
Chief Executive Officer | 3 |
Founder | 2 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
BIOARCTIC AB | Health Technology |
QUIAPEG PHARMACEUTICALS HOLDING AB | Health Technology |
Empresas privadas | 3 |
---|---|
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
Ryda Bruk AB
Ryda Bruk AB Miscellaneous Commercial ServicesCommercial Services Part of Beijerinvest AB, Ryda Bruk AB is a consulting services provider. The company is based in Heby, Sweden. | Commercial Services |
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- Hans Marcus Bosson
- Experiencia